NewAmsterdam Pharma Company NV
NAMS
查看详细走势图
34.300USD
+2.240+6.99%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.88B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.99%
5天
+10.22%
1月
-3.24%
6月
+49.39%
今年开始到现在
-2.22%
1年
+69.89%
查看详细走势图
TradingKey NewAmsterdam Pharma Company NV股票评分
单位: USD 更新时间: 2026-02-06操作建议
NewAmsterdam Pharma Company NV当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名24/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价48.77。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
NewAmsterdam Pharma Company NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
NewAmsterdam Pharma Company NV亮点
亮点风险
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
业绩增长期
公司处于发展阶段，最新年度总收入45.56M美元
利润高增长
公司净利润处于行业前列，最新年度总收入45.56M美元
估值低估
公司最新PE估值-16.80，处于3年历史低位
机构减仓
最新机构持股117.45M股，环比减少5.40%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值479.00
分析师目标
根据
15
位分析师
买入
评级
48.769
目标均价
+47.88%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NewAmsterdam Pharma Company NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NewAmsterdam Pharma Company NV简介
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
公司代码NAMS
公司NewAmsterdam Pharma Company NV
CEODavidson (Michael Harvey)
网址https://ir.newamsterdampharma.com/
相关品种
